| Bioactivity | Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease[1]. | ||||||||||||
| Target | CXCR2 | ||||||||||||
| In Vivo | Assessment of Pharmacokinetics (PK) profile of Vimnerixin in rat and dog[1]. In Vivo PK | ||||||||||||
| Name | Vimnerixin | ||||||||||||
| CAS | 1418112-77-2 | ||||||||||||
| Formula | C19H25FN4O5S2 | ||||||||||||
| Molar Mass | 472.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873. |
Vimnerixin
CAS: 1418112-77-2 F: C19H25FN4O5S2 W: 472.55
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin h
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.